Arctic Bioscience - Share Issue/Capital Change 2025

Arctic Bioscience - Share capital increase registered

Reference is made to the stock exchange release published by Arctic Bioscience

3[rd] February 2025 regarding Board approval of share capital increase related

to the exercise of debt conversion rights and corresponding issuance of new

shares in Arctic Bioscience.

The share capital increase has now been registered with the Norwegian Register

of Business Enterprises. As a result, the new share capital of Arctic Bioscience

has increased from NOK 2 536 955,20 to NOK 2 668 934,00, divided into 26 689 340

shares, each having a nominal value of NOK 0,10.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant